enGene Therapeutics
ENGN
57 hedge funds and large institutions have $530M invested in enGene Therapeutics in 2025 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 6 closing their positions.
333% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 6
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
90% more capital invested
Capital invested by funds: $279M → $530M (+$251M)
54% more funds holding
Funds holding: 37 → 57 (+20)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
7.82% more ownership
Funds ownership: 79.81% → 87.63% (+7.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$30.2M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$26.7M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$17.1M |
| 4 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$17M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$28.1M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$7.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.83M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.18M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.42M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
51
PFS Partners
Mine Hill,
New Jersey
| $99.3K | +$16K | +2,000 | +22% |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| $71K | – | – | – |
|
53
JP Morgan Chase
New York
| $23.6K | +$20.9K | +2,614 | New |
|
54
Citigroup
New York
| $15.2K | +$13.5K | +1,687 | +168,700% |
|
55
UBS Group
Zurich,
Switzerland
| $14.4K | +$12.8K | +1,597 | New |
|
|
MCM
56
MAI Capital Management
Independence,
Ohio
| $7.01K | – | – | – |
|
|
SS
57
SBI Securities
Tokyo,
Japan
| $253 | -$24 | -3 | -10% |
|
|
FLSM
58
Frazier Life Sciences Management
Palo Alto,
California
| – | -$7.9M | -1,157,380 | Closed |
|
|
59
Adage Capital Partners
Boston,
Massachusetts
| – | -$6.83M | -1,000,000 | Closed |
|
|
60
Bank of America
Charlotte,
North Carolina
| – | -$4.42M | -647,192 | Closed |
|
|
SFM
61
Sphera Funds Management
Tel Aviv,
Israel
| – | -$3.45M | -504,409 | Closed |
|
62
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$75.6K | -11,074 | Closed |
|
63
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$68.3K | -10,000 | Closed |
|
ENGN Hedge Fund Activity: Q4 2025 in Review
57 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q4 2025, worth a combined $530M — up 90% from $279M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ENGN positions and 6 closed out — a net gain of 20 holders — while 17 added to existing stakes and 8 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $30.2M. The largest seller was Kynam Capital Management, cutting an estimated $28.1M.
- 57 institutional investors held enGene Therapeutics (ENGN) as of Q4 2025, up from 37 in Q3 2025.
- Funds reported $530M of enGene Therapeutics stock for Q4 2025, up 90% quarter-over-quarter.
- 26 funds opened new enGene Therapeutics positions in Q4 2025 and 6 closed out, a net change of +20 holders.
- The largest enGene Therapeutics buyer in Q4 2025 was Perceptive Advisors, an estimated $30.2M added.
- The largest enGene Therapeutics seller in Q4 2025 was Kynam Capital Management, an estimated $28.1M sold.
Based on aggregated 13F filings for Q4 2025.